Topic overview

Start with the big picture

The lesson begins with epidemiology, risk and protective factors, and screening approaches for people at average risk. It then covers tumor location and molecular subtypes, including the clinical relevance of MSI-H/dMMR and RAS or BRAF V600E findings. TNM stage guides the broad treatment pathway: adjuvant chemotherapy is considered in stage II–III disease, while stage IV care may involve systemic therapy and selected procedures. The treatment overview includes established chemotherapy combinations, targeted agents, and immunotherapy options, alongside selected stage II high-risk features. Drug-safety topics include oxaliplatin neuropathy, fluoropyrimidine toxicities and DPD deficiency screening, and irinotecan-related concerns. This preview introduces those themes; the full lesson develops them in greater detail.